Search

Your search keyword '"Zettl, Uwe"' showing total 44 results

Search Constraints

Start Over You searched for: Author "Zettl, Uwe" Remove constraint Author: "Zettl, Uwe" Language undetermined Remove constraint Language: undetermined
44 results on '"Zettl, Uwe"'

Search Results

1. Impact and Protection of GNSS Interference: Resilient Positioning in Next Generation Satellite-Based Railway Train Control

2. sj-docx-5-taw-10.1177_20420986221143830 – Supplemental material for Therapy of women with multiple sclerosis: an analysis of the use of drugs that may have adverse effects on the unborn child in the event of (unplanned) pregnancy

3. sj-docx-2-taw-10.1177_20420986221143830 – Supplemental material for Therapy of women with multiple sclerosis: an analysis of the use of drugs that may have adverse effects on the unborn child in the event of (unplanned) pregnancy

4. sj-docx-3-taw-10.1177_20420986221143830 – Supplemental material for Therapy of women with multiple sclerosis: an analysis of the use of drugs that may have adverse effects on the unborn child in the event of (unplanned) pregnancy

5. sj-docx-4-taw-10.1177_20420986221143830 – Supplemental material for Therapy of women with multiple sclerosis: an analysis of the use of drugs that may have adverse effects on the unborn child in the event of (unplanned) pregnancy

6. sj-docx-1-taw-10.1177_20420986221143830 – Supplemental material for Therapy of women with multiple sclerosis: an analysis of the use of drugs that may have adverse effects on the unborn child in the event of (unplanned) pregnancy

7. sj-docx-1-taw-10.1177_20420986221143830 – Supplemental material for Therapy of women with multiple sclerosis: an analysis of the use of drugs that may have adverse effects on the unborn child in the event of (unplanned) pregnancy

8. sj-docx-3-taw-10.1177_20420986221143830 – Supplemental material for Therapy of women with multiple sclerosis: an analysis of the use of drugs that may have adverse effects on the unborn child in the event of (unplanned) pregnancy

9. sj-docx-5-taw-10.1177_20420986221143830 – Supplemental material for Therapy of women with multiple sclerosis: an analysis of the use of drugs that may have adverse effects on the unborn child in the event of (unplanned) pregnancy

10. Seizure Semiology in Antibody-Associated Autoimmune Encephalitis

11. sj-docx-1-taj-10.1177_20406223221108391 – Supplemental material for Associated factors of potential drug-drug interactions and drug–food interactions in patients with multiple sclerosis

12. sj-docx-1-taj-10.1177_20406223221108391 – Supplemental material for Associated factors of potential drug-drug interactions and drug–food interactions in patients with multiple sclerosis

13. sj-pdf-4-tan-10.1177_1756286420975642 – Supplemental material for Therapeutic plasma exchange in steroid-refractory multiple sclerosis relapses. A retrospective two-center study

14. sj-docx-2-msj-10.1177_13524585211039753 – Supplemental material for Time to diagnosis in multiple sclerosis: Epidemiological data from the German Multiple Sclerosis Registry

15. sj-pdf-1-taj-10.1177_20406223211024366 – Supplemental material for Rituximab versus mitoxantrone: comparing effectiveness and safety in advanced relapsing multiple sclerosis

16. sj-pdf-2-tan-10.1177_1756286420975642 – Supplemental material for Therapeutic plasma exchange in steroid-refractory multiple sclerosis relapses. A retrospective two-center study

17. sj-pdf-3-tan-10.1177_1756286420975642 – Supplemental material for Therapeutic plasma exchange in steroid-refractory multiple sclerosis relapses. A retrospective two-center study

18. sj-pdf-1-taj-10.1177_20406223211024366 – Supplemental material for Rituximab versus mitoxantrone: comparing effectiveness and safety in advanced relapsing multiple sclerosis

19. sj-pdf-3-tan-10.1177_1756286420975642 – Supplemental material for Therapeutic plasma exchange in steroid-refractory multiple sclerosis relapses. A retrospective two-center study

20. sj-pdf-4-tan-10.1177_1756286420975642 – Supplemental material for Therapeutic plasma exchange in steroid-refractory multiple sclerosis relapses. A retrospective two-center study

21. sj-docx-1-msj-10.1177_13524585211039753 – Supplemental material for Time to diagnosis in multiple sclerosis: Epidemiological data from the German Multiple Sclerosis Registry

22. sj-docx-1-tan-10.1177_17562864211048336 – Supplemental material for Treatment patterns in pediatric patients with multiple sclerosis in Germany—a nationwide claim-based analysis

23. sj-pdf-1-tan-10.1177_1756286420975642 – Supplemental material for Therapeutic plasma exchange in steroid-refractory multiple sclerosis relapses. A retrospective two-center study

24. sj-docx-1-msj-10.1177_13524585211046739 – Supplemental material for Epilepsy as a predictor of disease progression in multiple sclerosis

25. sj-pdf-2-tan-10.1177_1756286420975642 – Supplemental material for Therapeutic plasma exchange in steroid-refractory multiple sclerosis relapses. A retrospective two-center study

26. sj-docx-1-msj-10.1177_13524585211039753 – Supplemental material for Time to diagnosis in multiple sclerosis: Epidemiological data from the German Multiple Sclerosis Registry

27. [Untitled]

28. sj-pdf-1-msj-10.1177_1352458520985118 – Supplemental material for Effect of applying inclusion and exclusion criteria of phase III clinical trials to multiple sclerosis patients in routine clinical care

29. Correction for Ostkamp et al., Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity

30. sj-pdf-1-tan-10.1177_1756286420975642 – Supplemental material for Therapeutic plasma exchange in steroid-refractory multiple sclerosis relapses. A retrospective two-center study

31. Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity

32. The story of aggressive multiple sclerosis

33. Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity

34. A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity

35. Genetic predisposition in anti-LGI1 and anti-NMDA receptor encephalitis

36. Is benign MS 'benign'

37. MSJ763541_supplementary_material – Supplemental material for Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis

38. Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk

39. MSJ799580_supplemental_table_1 – Supplemental material for Symptomatology and symptomatic treatment in multiple sclerosis: Results from a nationwide MS registry

40. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

41. Pharmacogenomic study in patients with multiple sclerosis

43. A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity

44. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Catalog

Books, media, physical & digital resources